[1]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.
Chu QS, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10419):2295-2306. doi:10.1016/S0140-6736(23)01613-6 FDA a...
FDA Expands Pembrolizumab Label for MelanomaThe FDA recently expanded its approval of pembrolizumab (Keytruda) to include the initial treatment of patients with unresectable or metastatic melanoma.L. Lawrence
Powles T, Csőszi T, Özgüroğlu M, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lan...
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X. 品牌介绍:• MCE (MedChemExpress) 拥有200 多种*仅有化合物库,我们致力于为*科研客户...
Tumors. Clin Cancer Res.2015Oct1;21(19):4286-93.[3]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7 4. Colombo N, ...
References 1. New efficacy data for non-clear cell renal cell carcinoma from KEYNOTE-B61 added to LENVIMA (lenvatinib) US label supporting KEYTRUDA + LENVIMA indication for the first-line treatment of adult patients with advanced RCC. News release. Eisai Inc. June 27, 2024. Accessed...
[3]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.
Chu QS, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10419):2295-2306. doi:10.1016/S0140-6736(23)01613-6 ...